West Reports Third-Quarter 2026 Results
PR Newswire•29/10/2026•06:00 ET
0
Key Highlights
- ➤Q3 net sales $874.5 million, up 8.7%; organic growth reached 11.9%
- ➤Adjusted-diluted EPS $2.66, up 35.7% year over year
- ➤Full-year net sales guidance raised to $3.41 billion-$3.42 billion
- ➤Full-year adjusted-diluted EPS guidance raised to $9.38-$9.48
- ➤HVP Components sales $466.7 million, up 19.7% year over year
Expert Statements
Michel Lagarde, President and Chief Executive Officer of West Pharmaceutical Services
“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”
Michel Lagarde, President and Chief Executive Officer of West Pharmaceutical Services
“I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”
Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance
EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2026.
Get started
Create a free account to read the full story.